SEATTLE, Feb. 01, 2018 (GLOBE NEWSWIRE) -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Maricann Group Inc.'s (CSE:MARI) (CNSX:MARI) (MARI.CN) (OTCQB:MRRCF) exposure to the global cannabis market. Maricann Group is a licensed producer of medical cannabis under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). The company has exposure to Europe, as well as attractive competitive advantages in both medical and adult-use cannabis sectors.



The Canadian cannabis industry is projected to reach C$22.6 billion in size over the coming years, according to Deloitte, driven by the legalization of adult-use marijuana. While most licensed producers are focused on the domestic market, the legalization of medical marijuana across much of Europe has opened the door to new opportunities. Investors may want to consider LPs focused on many areas of both Canada and Europe.

Significant Production Capacity

After securing a cultivation license in March of 2014, Maricann Group began selling dried cannabis in January of 2015 and extracts in October of 2016. In addition to Canada, the company’s Germany-based Ebersbach facility targets the massive European market with 820,000 sq. ft. of cultivation space and over 12,000 patients.

The company has near-term plans to expand its production with a brand new, state-of-the-art facility on 100 acres of land in Ontario. During the second quarter of this year, management plans to complete the first phase of construction with 22,500 kilograms per year of capacity at a cost of $1.34 per gram. The company plans to further expand in the second half of the year to 942,000 sq. ft. of space with 95,000 kilograms per year of capacity at 60 cents per gram.

Unlike many Canadian cultivation facilities, the company’s low-cost and high-efficiency facility will leverage cutting-edge robotics and automation technology to ease compliance, enhance quality, and reduce costs. This could translate to higher quality products for consumers and higher margin products for investors. Management believes that this level of automation is unparalleled in the cannabis industry and sets a new standard for quality and excellence.

Recreational & Medical Focus

Maricann Group has developed educational programming for patients and healthcare professionals. Through exclusive pharmacy agreements with ~20 percent of the country’s pharmacies, the company aims to become a leading provider of cannabis at physical point-of-sale locations that patients trust. Management anticipates a full national launch in April of this year, which coincides nicely with its Langton facility coming online.

“Pharmacists consistently rank at very high levels among the most trusted professionals and [a November 2017 initiative with a national provider that services pharmacies across Canada] will place participating pharmacists at the forefront of patient care as it relates to the use of medicinal cannabis,” said Maricann Group CEO Ben Ward in a press release.

While pharmacies target the medical side of the business, the company signed two brand partnership agreements targeting the recreational side of the market. The company’s partnership with International Cannabrands Inc. (CSE:JUJU.A) provides it access with the Julian Marley name and JuJuRoyal brand. The company also has a partnership with Rare Dankness, which is an award-winning and globally-recognized brand in both the US and Europe.

Innovative Research & Development

A major problem facing cannabinoid researchers is that the compound isn’t water soluble, which makes it difficult to develop oral dosing mechanisms. Cannabinoids are a fat-soluble compound that have low solubility, which leads to low dissolution rates and significant first-pass liver metabolism. This results in low and unpredictable oral cannabinoid bioavailability, as well as high inter- and intra-subject variability and the lack of dose proportionality.

In August of 2017, Maricann Group acquired NanoLeaf Technologies, a biotech company possessing licensing rights to a number of globally patented technologies that provide proven pharmaceutical, nutraceutical, cosmetic, and functional beverage drug delivery formulations. The company’s Vesisorb is the first standardized dose cannabinoid soft gel capsule with a nano-dispersed carrier for the drug that is ideal for ingestional bioavailability.

“The acquisition of NanoLeaf Technologies will significantly enhance Maricann’s growth trajectory by expanding our product portfolio, delivering access to new markets, and strengthening our pipeline of future products, making us leaders in the drug delivery of cannabinoids,” said CEO Ben Ward in a press release announcing the acquisition.

Looking Ahead

Maricann Group Inc. (CSE:MARI) (OTCQB:MRRCF) represents a compelling investment opportunity in the global cannabis industry. With both Canadian and European operations, the company is well positioned to expand around the world. Its innovative drug delivery platform and adult-use branding also opens the door to both areas of the market.

For more information, visit the company’s website at www.maricann.ca.

Please follow the link to read the full article: http://www.cannabisfn.com/maricann-group-diversified-opportunity-global-cannabis-industry/

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Frank Lane

206-369-7050

flane@cannabisfn.com